, Tracking Stock Market Picks
Enter Symbol:
Rating: MNTA
Buy $15
down 8.00 %

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) reiterated to Buy with price target $15 by UBS

Wednesday,  Feb 18, 2015  2:25 PM ET by Kristen Bailey

The UBS advised against investing in this stock and the price has fallen for a loss. The price fell from $13.62 on 06/06/2013 to $12.52 on 02/18/2015. UBS reiterated Momenta Pharmaceuticals,
Inc. (NASDAQ: MNTA) to Buy with price target $15 with today's price of $12.52. UBS rated Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) to Buy with price target $17 on 06/06/2013, when the price was $13.62. Momenta Pharmaceuticals, Inc.'s stock price lost 8% since then.
By following the previous UBS's recommendation on MNTA, you would have lost 8% in 622 days.

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy